Sector
PharmaceuticalsOpen
₹440.7Prev. Close
₹440.4Turnover(Lac.)
₹3,188.79Day's High
₹444.4Day's Low
₹436.0552 Week's High
₹484.352 Week's Low
₹328.15Book Value
₹78.03Face Value
₹2Mkt Cap (₹ Cr.)
23,852.41P/E
105.81EPS
4.16Divi. Yield
0.1825 Apr 2024
12:00 AM
BookCloser
25 Apr 2024
12:00 AM
Dividend
Dividend Amount: 0.4
Record Date: 08 May, 2024
25 Apr 2024
12:00 AM
AGM
Announcement Date: 25 Apr, 2024
18 Apr 2024
12:00 AM
Board Meeting
Agenda : Audited Result
| Y/e 31 Mar( In .Cr) | Mar-2024 | Mar-2023 | Mar-2022 | Mar-2021 |
|---|---|---|---|---|
Equity Capital | 107.79 | 107.73 | 107.47 | 107.32 |
Preference Capital | 0 | 0 | 0 | 0 |
Reserves | 4,099.26 | 3,949.09 | 3,280.74 | 2,604.92 |
Net Worth | 4,207.05 | 4,056.82 | 3,388.21 | 2,712.24 |
Minority Interest |
| Y/e 31 Mar( In .Cr) | Mar-2022 | Mar-2021 | Mar-2020 | Mar-2018 |
|---|---|---|---|---|
Revenue | 4,707.04 | 4,768.72 | 2,797.33 | 2,026.84 |
yoy growth (%) | -1.29 | 70.47 | 38.01 | 7.13 |
Raw materials | -2,208.56 | -2,175.13 | -1,402.54 | -1,056.4 |
As % of sales | 46.92 | 45.61 | 50.13 | 52.12 |
Employee costs | -445.14 | -401.88 | -323.99 | -238.14 |
| Y/e 31 Mar( In .Cr) | Mar-2022 | Mar-2021 | Mar-2020 | Mar-2018 |
|---|---|---|---|---|
Profit before tax | 975.41 | 1,274.63 | 304.48 | 240.9 |
Depreciation | -235.48 | -196.64 | -183.85 | -121.23 |
Tax paid | -225.32 | -318.52 | -37.43 | -67.76 |
Working capital | 145.83 | 684.91 | 246.73 | 42.81 |
Other operating items |
| Y/e 31 Mar | Mar-2022 | Mar-2021 | Mar-2020 | Mar-2018 |
|---|---|---|---|---|
Growth matrix (%) | ||||
Revenue growth | -1.29 | 70.47 | 38.01 | 7.13 |
Op profit growth | -14.88 | 164.78 | 39.5 | -1.22 |
EBIT growth | -20.08 | 241.8 | 23.97 | -7.49 |
Net profit growth | -21.54 | 258.03 | 54.23 | -13.41 |
| Particulars (Rupees in Crores.) | Mar-2024 | Mar-2023 | Mar-2022 | Mar-2021 | Mar-2020 |
|---|---|---|---|---|---|
Gross Sales | 5,040.83 | 6,040.55 | 4,935.57 | 4,813.51 | 2,831.72 |
Excise Duty | 0 | 0 | 0 | 0 | 0 |
Net Sales | 5,040.83 | 6,040.55 | 4,935.57 | 4,813.51 | 2,831.72 |
Other Operating Income | 0 | 0 | 0 | 0 | 0 |
Other Income | 26.34 | 6 | 15.3 | 23.66 | 5.92 |
Company Name | LTP (₹) | P/E (%) | Mkt.Cap (₹Cr.) | NP Qtr (₹Cr.) | Div.Yield (%) | Sales Qtr (₹.Cr) | Book Value (₹) |
|---|---|---|---|---|---|---|---|
Sun Pharmaceuticals Industries Ltd SUNPHARMA | 1,568.65 | 123.31 | 3,76,323.69 | 867.6 | 0.86 | 5,536.99 | 98.75 |
Divis Laboratories Ltd DIVISLAB | 4,519.8 | 76.17 | 1,19,994.45 | 531 | 0.66 | 2,259 | 507.93 |
Cipla Ltd CIPLA | 1,485.5 | 32.29 | 1,19,928.54 | 1,038.4 | 0.57 | 3,444.92 | 346.41 |
Zydus Lifesciences Ltd ZYDUSLIFE | 1,144.45 | 33.51 | 1,15,173.54 | 1,405.2 | 0.26 | 3,172.6 | 156.19 |
Dr Reddys Laboratories Ltd DRREDDY | 6,636 | 25.85 | 1,10,759.07 | 1,034.8 | 0.6 | 5,081.8 | 1,458.96 |
Figures of Market Capital(Mar Cap), Quarterly Net Profit(NP Qtr) and Quarterly Sales(Sales Qtr) are in ₹ Cr.
Executive Director & CEO
CHAVA SATYANARAYANA
Executive Director & CFO
VENKATA RAVI KUMAR VANTARAM
Independent Director
Aruna Bhinge
Independent Director
Rajesh Koshy Chandy
Chairman & Independent Directo
Ravindranath Kancherla
Executive Director
Venkata Lakshmana Rao Chunduru
Independent Director
Karnam Sekar
Executive Director
KRISHNA CHAITANYA CHAVA
Vice President & CS
G Venkateswar Reddy
Executive Director
Soumya Chava
Tel: -
Website: -
Email: -
Tel: -
Website: -
Email: -
Reports by Laurus Labs Ltd
Summary
Laurus Labs is a science-led, fully integrated pharmaceutical and biotechnology manufacturing company with a leadership position in generic active pharmaceutical ingredients (APIs) in selected high-growth therapeutic areas of anti-retrovirals (ARVs), Hepatitis C and Oncology. The company also manufactures APIs in oncology and other therapeutic areas, such as anti-asthma, ophthalmology, antidiabetics, cardiovascular, proton pump inhibitors (PPIs) amongst others. The company currently operates 4 manufacturing facilities in Visakhapatnam, Andhra Pradesh. Three of these facilities manufacture APIs and ingredients, while the fourth facility produces Finished Dosage Formulations (FDFs) and one API. The companys strategic and early investments in R&D and manufacturing infrastructure has enabled it to become one of the leading suppliers of APIs in the ARV therapeutic area to multi-national pharmaceutical formulation companies which cater to the large and fast-growing donor-funded access-to-medicines markets of Sub-Saharan Africa, South-East Asia and Latin America. The company also has growing synthesis and nutraceutical/ cosmeceutical ingredients businesses. Further, it is increasingly focused towards growing its integrated generics finished dosage forms (FDFs) business in which it has made significant investments.Laurus Labs operates in four business lines: Generics - APIs, Generics - FDFs, Synthesis and Ingredients. Its Generics - API business comprises the development, manufacture
Read More
What is the Laurus Labs Ltd share price today?
The Laurus Labs Ltd shares price on N/A is Rs.₹442.75 today.
What is the Market Cap of Laurus Labs Ltd?
Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Laurus Labs Ltd is ₹23871.28 Cr. as of 22 Jul ‘24
What is the PE and PB ratio of Laurus Labs Ltd?
The PE and PB ratios of Laurus Labs Ltd is 105.81 and 5.64 as of 22 Jul ‘24
What is the 52 Week High and Low of Laurus Labs Ltd?
The 52-week high/low is the highest and lowest price at which a Laurus Labs Ltd stock has traded during that given time period (similar to 1 year) and is considered as a technical indicator. The 52 week high and low of Laurus Labs Ltd is ₹328.15 and ₹484.95 as of 22 Jul ‘24
What is the CAGR of Laurus Labs Ltd?
Laurus Labs Ltd's CAGR for 5 Years at 44.41%, 3 Years at -12.84%, 1 Year at 25.43%, 6 Month at 6.78%, 3 Month at 3.26% and 1 Month at 2.34%.
What is the shareholding pattern of Laurus Labs Ltd?
The shareholding pattern of Laurus Labs Ltd is as follows:
Promoters - 27.18 %
Institutions - 39.23 %
Public - 33.59 %
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Securities Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2024, IIFL Securities Ltd. All Rights Reserved
www.indiainfoline.com is part of the IIFL Group, a leading financial services player and a diversified NBFC. The site provides comprehensive and real time information on Indian corporates, sectors, financial markets and economy. On the site we feature industry and political leaders, entrepreneurs, and trend setters. The research, personal finance and market tutorial sections are widely followed by students, academia, corporates and investors among others.
Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
